HomeNewsBusinessMarketsGlobal brokerage view: 11% rally possible in Maruti stock; Titan downgraded to underperform

Global brokerage view: 11% rally possible in Maruti stock; Titan downgraded to underperform

The market has done well during recent times, caution may be required in the short-term, say experts.

November 06, 2019 / 11:54 IST
Story continues below Advertisement

Indian market is trading in range after the recent surge that pushed the Sensex to a record high of 40,483.

Story continues below Advertisement

The index is still holding above 40,000 though weighed down by muted global cues, but the Nifty slipped below its crucial support at 11,900.

The hopes of a trade deal have fizzled out for now and with no big triggers lined up, investors should stay cautious in the near-term. The recent rally was led by good Q2 results and in expectation of more reforms.

Tech Mahindra: Neutral| Target Rs 680
UBS maintained its rating on Tech Mahindra post-September quarter results, with a target of Rs 680. The global investment bank expects a positive reaction to the revenue beat, and operating margin guide.
The management expects the revenue momentum to be strong in H2, and margin at 100-150 bps below FY19 levels. The FY21 EBIT margin is expected to improve to 15 percent. Strong Q2, as well as positive H2 guidance, should buoy sentiment, said the note.

Dabur India: Buy| Target raised to Rs 575 from Rs 515 earlier
CLSA maintained its buy rating on Dabur India post-September quarter results and raised its target to Rs 575 from Rs 515.

The results were ahead of estimates led by better margins. India volume growth stood at 4.8 percent, which reflected a tough macro environment.

Ex-foods growth was more respectable at 7.4 percent. But, worst may well be over, as there has been a sequential improvement, said the CLSA note. The global investment bank continues to like the company’s portfolio and management strategy around growth.

Biocon: Buy| Target Rs 280
HSBC maintained its buy rating on Biocon, with a target price of Rs 280. The rival drug approval raised a challenge for Fulphila.

Sandoz received USFDA approval for Ziextenzo. It will be critical for Fulphila to recover market share in the Pegfilgrastim market. The launch of biosimilar Trastuzumab in the US will be a key event to watch in the near-term.

Punjab National Bank: Underperform| Target cut to Rs 55 from Rs 65
Credit Suisse maintained its underperform rating on PNB post-September quarter results and reduced its target to Rs 55 from Rs 65.

The stock price keeping pace with book value decline. The loan growth remains muted (+1% QoQ), and pre-provision profitability remained weak.

The NIM remains flat at 2.4 percent, and unlike the expansion seen at other banks in Q2, the global investment bank slashed FY21 EPS estimate by 40 percent.

Disclaimer: The above report is compiled from information available on public platforms, and CNBC-TV18. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.